![]() This article by Simply Wall St is general in nature. Alternatively, email editorial-team (at). ![]() Have feedback on this article? Concerned about the content? Get in touch with us directly. At Simply Wall St, we have a full range of analyst estimates for Horizon Therapeutics going out to 2024, and you can see them free on our platform here.īefore you take the next step you should know about the 3 warning signs for Horizon Therapeutics that we have uncovered. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting sales are tracking in line with expectations - although our data does suggest that Horizon Therapeutics' revenues are expected to perform worse than the wider industry. The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Factoring in the forecast slowdown in growth, it seems obvious that Horizon Therapeutics is also expected to grow slower than other industry participants. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 12% annually. We would highlight that Horizon Therapeutics' revenue growth is expected to slow, with the forecast 7.2% annualised growth rate until the end of 2022 being well below the historical 28% p.a. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Horizon Therapeutics is an easy business to forecast or the the analysts are all using similar assumptions. The most optimistic Horizon Therapeutics analyst has a price target of US$162 per share, while the most pessimistic values it at US$132. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. It might be a surprise to learn that the consensus price target was broadly unchanged at US$142, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. ![]() Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.99b and earnings per share (EPS) of US$4.08 in 2022. Statutory per-share earnings are expected to be US$3.75, roughly flat on the last 12 months. Taking into account the latest results, the consensus forecast from Horizon Therapeutics' eleven analysts is for revenues of US$3.97b in 2022, which would reflect a credible 5.4% improvement in sales compared to the last 12 months. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |